Title of Collaborative Activity: |
SARS-CoV-2Interagency Working Group: Therapeutics, Diagnostics, Vaccines. DCR involved in Thx and DX (SIG) |
Description of Collaborative Activity: |
Developed to monitor the impact of variants on efficacy of MCMs |
Type of Collaborative Activity: |
Committee, Advisory Group, or Work Group
|
Year the Collaborative Activity Originated: |
2021 |
NIH Participating Institutes/Centers/Office of the Director: |
NIAID |
HHS Agency Collaborators on this Activity: |
NIH, FDA, ASPR |
